In this review:
Adding ribociclib in premenopausal hormone receptor+, HER2– advanced breast cancer
Real-life outcomes for metastatic luminal HER2-negative breast cancer
Trastuzumab in high-risk, nonmetastatic, HER2 nonamplified breast cancer with CTCs
Locoregional breast cancer recurrence risk factors
Pathological CR correlated with nodal status after neoadjuvant treatment in HER2+ TNBC
Low-dose aspirin increases contralateral breast cancer risk
Psychological group intervention for fear of cancer recurrence
Neoadjuvant RT in high-risk or locally advanced breast cancer
Boost dose and cosmetic outcomes after breast-conserving therapy
Please login below to download this issue (PDF)